Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SIB-IMRT with pemetrexed plus cisplatin in stage III non-small cell lung cancer
ChiCTR-ONRC-13003386Phase 2Completed
- Sponsor
- Shandong Cancer Hospital
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed and cisplatin in non-small cell lung cancer (NSCLC), sponsored by Shandong Cancer Hospital. Primary endpoint: Survival rate. Started Jul 2013; status: completed.
02
Drugs
pemetrexedcisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-ONRC-13003386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONRC-13003386.